santa cruz biotechnology, inc.
SCBT Logo

Welcome!        Items in Cart     Quick Order

Mdr-3 (P3II-26) Antibody: sc-58221

 |  Datasheet
  • mouse monoclonal IgG2b, 500 µl supernatant
  • recommended for detection of Mdr-3 of human origin by WB, IF and FCM
 
Additional Mdr Antibodies ...
 
Ordering Information
Recommended Support Products:
(click button of application of choice)
WB   IF   FCM   siRNA  
 
Species Gene Name Gene ID Chromosome Location Isoform (mRNA) Accession # Protein Accession # OMIM™ Number
Human ABCB4 5244 7q21.12 NM_000443, NM_018849, NM_018850 P21439
602347
 
Set Currency

 Ordering Information
Product NameCatalog #UnitPriceQtyAddFavorites
Mdr-3 (P3II-26) sc-58221 500 µl supernatant $279
 siRNA Gene Silencers (click product name for more information)
Product NameCatalog #UnitPriceQtyAddFavorites
Mdr-3 siRNA (h) sc-37015 10 µM $258
Mdr-3 (h)-PR sc-37015-PR 10 µM $23
 shRNA Plasmids (click product name for more information)
Product NameCatalog #UnitPriceQtyAddFavorites
Mdr-3 shRNA Plasmid (h) sc-37015-SH 20 µg $520
 shRNA Lentiviral Particles (click product name for more information)
Product NameCatalog #UnitPriceQtyAddFavorites
Mdr-3 shRNA (h) Lentiviral Particles sc-37015-V 200 µl $625

Mdr-3 Background Information
Cells selected for resistance to a single cytotoxic drug may become cross-resistant to a broad range of drugs having different structures and cellular targets. This phenomenon is called multiple drug resistance (MDR). The MDR proteins (Mdrs) are members of a highly conserved superfamily of ATP-binding cassette transport proteins. Mdr functions as an energy-dependent efflux pump for structurally diverse agents ranging from ions to peptides and is implicated in the development of the multiple drug resistance observed in human cancer cells following prolonged chemotherapy. The classic form of MDR is associated with an increase in the Mdr protein, but not all cases of MDR can be attributed to a rise in Mdr levels. Mdr-3 (also known as ABCB4) is a member of the Mdr family that may be associated with a more malignant phenotype in B cell lymphocytic leukemias.